同方康泰(01312.HK):康樂製藥已恢復生產及製作原料藥磷酸氯喹
格隆匯2月3日丨同方康泰(01312.HK)宣佈,集團接獲中國工業和信息化部消費品司、重慶市經濟和信息化委員會與重慶市長壽區經濟和信息化委員會的通知,磷酸氯喹(Chloroquine Phosphate)被測試及證實就對抗新型冠狀病毒感染的肺炎(Pneumonia infected by Novel Coronavirus) ("2019新型冠狀病毒")有一定的療效。
公司間接非全資附屬公司重慶康樂製藥有限公司("康樂製藥"),早前已獲國家藥品監督管理局(前稱國家食品藥品監督管理總局)認可為生產原料藥磷酸氯喹(Active PharmaceuticalIngredients Chloroquine Phosphate)的單位。監於對抗2019新型冠狀病毒有一定的療效,康樂製藥被工業和信息化部消費品司要求儘快恢復原料藥磷酸氯喹(Active Pharmaceutical IngredientsChloroquine Phosphate)的生產及製作。因應2019新型冠狀病毒的爆發,重慶市長壽區新型冠狀病毒感染的肺炎防控工作領導小組早前頒令區內企業原則上不得早於2020年2月10日之前復工,除非涉及疫情防控必需的行業及涉及市民生活和城市運行必需的行業。康樂製藥是被要求早於上述日期前儘快復工的。集團獲進一步通知康樂製藥被認可生產的原料藥磷酸氯喹(Active Pharmaceutical Ingredients Chloroquine Phosphate)現已被納入中央醫藥儲備的名單中。
於公告日期,康樂製藥已恢復生產及製作原料藥磷酸氯喹(Active Pharmaceutical IngredientsChloroquine Phosphate)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.